Bank of New York Mellon Corp boosted its position in shares of Atara Biotherapeutics (NASDAQ:ATRA) by 4.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 129,237 shares of the biotechnology company’s stock after buying an additional 5,415 shares during the quarter. Bank of New York Mellon Corp’s holdings in Atara Biotherapeutics were worth $2,339,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Pacific Heights Asset Management LLC purchased a new position in Atara Biotherapeutics during the fourth quarter worth about $453,000. Neuberger Berman Group LLC raised its stake in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after purchasing an additional 147,061 shares during the period. Alps Advisors Inc. raised its stake in Atara Biotherapeutics by 12.7% during the fourth quarter. Alps Advisors Inc. now owns 33,904 shares of the biotechnology company’s stock worth $614,000 after purchasing an additional 3,809 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Atara Biotherapeutics by 20.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 104,612 shares of the biotechnology company’s stock worth $1,894,000 after purchasing an additional 17,995 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Atara Biotherapeutics during the third quarter worth about $170,000. 76.88% of the stock is currently owned by institutional investors.
Shares of ATRA opened at $40.60 on Monday. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $49.90. The stock has a market cap of $1,638.45, a price-to-earnings ratio of -10.15 and a beta of 2.55.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.15). equities research analysts anticipate that Atara Biotherapeutics will post -3.58 EPS for the current year.
A number of brokerages have commented on ATRA. BidaskClub downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, April 6th. ValuEngine upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Guggenheim started coverage on shares of Atara Biotherapeutics in a research report on Thursday, March 15th. They set a “neutral” rating for the company. Finally, Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and an average target price of $37.50.
In related news, Director Carol Giltner Gallagher sold 1,183 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $46.50, for a total value of $55,009.50. Following the completion of the transaction, the director now owns 111,286 shares in the company, valued at $5,174,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 48,500 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $34.58, for a total transaction of $1,677,130.00. Following the completion of the transaction, the chief executive officer now owns 348,978 shares of the company’s stock, valued at approximately $12,067,659.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 245,424 shares of company stock valued at $9,872,689. Company insiders own 16.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Has $2.34 Million Holdings in Atara Biotherapeutics (ATRA)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/16/bank-of-new-york-mellon-corp-has-2-34-million-holdings-in-atara-biotherapeutics-atra.html.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.